Navigation Links
Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
Date:10/29/2008

Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's Web site: http://www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(R) (lisdexamfetamine dimesylate) (Attention Deficit Hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on the Company's ADHD franchise; patents, including but not limited to, legal challenges relating to the Company's ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); the Company's ability to secure new products for commercialization and/or development; the Company's proposed offer for Jerini AG, including but not limited to, the Company's ability to successfully complete the offer and integrate Jerini AG, as well as realize the anticipated benefits of the acquisition; and other risks and uncertainties detailed from time to time in the Company's
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
2. Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization Schedules
3. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
4. Presentations From Recent Heart Rhythm Society Meeting Validate the Safety and Efficacy of Ablation Frontiers Technology in 230 Patients
5. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
6. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
7. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
8. Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia
9. Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing
10. Recent Studies Suggest Popular Diet Pill Relacore Reduces Acne Breakouts
11. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... -- Codman Neuro*, part of DePuy Synthes Companies of ... embolic coils for the treatment of brain aneurysms, supported ... stability and provide an optimized detachment zone for coils ... Society of NeuroInterventional Surgery (SNIS) 12 th Annual ... finishing coils used during a minimally invasive endovascular procedure ...
(Date:7/28/2015)... Amgen (NASDAQ: AMGN ) announced that ... share dividend for the third quarter of 2015. The ... all stockholders of record as of the close of ... Amgen Amgen is committed to unlocking the potential of ... developing, manufacturing and delivering innovative human therapeutics. This approach ...
(Date:7/28/2015)... BILLERICA, Mass. , July 28, 2015  Insulet ... insulin pump technology with its OmniPod ® Insulin ... has been appointed to Insulet,s Board of Directors. ... of top-tier healthcare experience to the Insulet Board. She ... of the Joslin Diabetes Center, the world,s largest diabetes ...
Breaking Medicine Technology:Codman Neuro Launches Family Of Coils For Treatment Of Brain Aneurysms 2Codman Neuro Launches Family Of Coils For Treatment Of Brain Aneurysms 3Codman Neuro Launches Family Of Coils For Treatment Of Brain Aneurysms 4Amgen Announces 2015 Third Quarter Dividend 2Amgen Announces 2015 Third Quarter Dividend 3Insulet Appoints Jessica Hopfield, PhD, to Board of Directors 2Insulet Appoints Jessica Hopfield, PhD, to Board of Directors 3
... Bionovo, Inc. (Nasdaq: BNVI ) announced today that ... fiscal year 2009 ended September 30, 2009 on Thursday, November ... web cast to review the financial results on Thursday, November ... access the call by dialing (800) 860-2442 or (412) 858-4600, ...
... AMSTERDAM, October 29 Amsterdam Molecular,Therapeutics ... entered into a development and commercialization agreement for,LPLchip(TM), a ... lipoprotein lipase deficiency (LPLD). AMT has developed Glybera(R) as,a ... In June of this year AMT ...
Cached Medicine Technology:AMT Starts Development LPLChip(TM) With Progenika 2AMT Starts Development LPLChip(TM) With Progenika 3
(Date:7/29/2015)... ... July 29, 2015 , ... ... entered into a partnership with 247Ergo, an ergonomics specialty firm. Purpose of the ... projects that the companies undertake could improve worker mobility, functionality and fitness levels. ...
(Date:7/29/2015)... Estates, IL (PRWEB) , ... July 29, 2015 , ... ... both benefit from two new products on Mercola.com: a vertical “garden tower” and enhanced ... which can be squeezed into small corners on a porch, balcony, or rooftop – ...
(Date:7/29/2015)... ... 29, 2015 , ... Indiana is known for basketball, the boyhood home of ... Indianapolis, which plans to expand across the state. , Ray Kennedy, owner of the ... in business and we should double our first year’s revenue. More importantly, we ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... seeking funding for a study on the potentially lifesaving impact of removing aluminum ... . , The research proposal is based on a successful pilot study ...
(Date:7/29/2015)... ... July 29, 2015 , ... Elizabeth ... in Sarasota to be chosen by the manufacturer to offer and perform ... injectable, non-invasive way to treat and eliminate double chin fat,” Dr. Callahan explained. ...
Breaking Medicine News(10 mins):Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 2Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 3Health News:Mercola.com Introduces NEW Garden Tower and Enhanced Mineral Solution for Healthy Plants 2Health News:Zerorez® Announces Plans to Roll Across Indiana—“The Crossroads of America.” 2Health News:Zerorez® Announces Plans to Roll Across Indiana—“The Crossroads of America.” 3Health News:Children's Medical Safety Research Institute Announces Innovative Study on Alzheimer’s Treatment Is Subject of Crowd Funding Campaign 2Health News:Children's Medical Safety Research Institute Announces Innovative Study on Alzheimer’s Treatment Is Subject of Crowd Funding Campaign 3Health News:SkinSmart Dermatology is First in Sarasota to Offer Kybella Treatments to Reduce Double Chin Fat 2Health News:SkinSmart Dermatology is First in Sarasota to Offer Kybella Treatments to Reduce Double Chin Fat 3
... was diagnosed with lung cancer has won $ 1 million in ... suffering from an inoperable lung cancer. ,Doctors have given ... At this juncture, he has won this lottery. But the irony ... paid $50,000 in annual installments over twenty years. ,Schenk ...
... University in Chicago claim that men who have undergone ... type// of dementia. This study was published in Cognitive ... on 106 men. Out of this, 25 developed a ... undergone vasectomy. According to the chief scientist of this ...
... new study suggests that patients who develop Parkinson's ... history includes alcohol// abuse may be more likely ... of medications used to treat their condition. ... hypersexuality, binge eating and pathological gambling—have been associated ...
... People who have multiple sclerosis (MS) for 10 years and have ... they// have “benign MS” and that their symptoms will likely not ... A new study shows that unfortunately this may not be correct. ... nearly half of those whose MS was benign at 10 years, ...
... Medicare coverage for colorectal cancer screening has increased, there ... a report published recently, some of these disparities are ... ,Colorectal cancer is the third most common ... with approximately 145,290 new cases in 2005, according to ...
... test that can distinguish between a pair of nearly ... treatment. ,Their report is published this week ... the National Academy of Sciences. ,"This simple ... quickly implemented in the clinic to benefit patients by ...
Cached Medicine News:Health News:Compulsive Gambling Linked to Parkinson's Disease Medications 2Health News:Disparities in Colon Cancer Screening Remain Among Medicare Patients 2Health News:A New Two-gene Test to Discern Similar Gastrointestinal Cancers 2
This is adapted to microplate or card....
ScanGel® Incubator...
... The ID-Micro Typing System™ ... for a broad range of ... include antibody screening and identification, ... phenotyping, compatibility testing, reverse serum ...
... 120 Mini-Vertical Gel System simplifies the process of ... format. It is able to run four gels ... To maximize utility and throughput, the 120 mini-vertical ... gels (W x L) at one time. The ...
Medicine Products: